The presented data should be considered a pilot study and prospective placebo-controlled trials are needed to investigate whether predictive biomarkers such as serum OPG levels, high seminal RANKL, or high Inhibin B or AMH can assist in the selection of the infertile men who may benefit from Denosumab treatment. The gene discussed is AMH; the disease is Infertility.